EVIO Labs Berkeley Ready for California's Phase 3 Cannabis Testing

The company is positioned to significantly benefit from California's cannabis testing regulations.

Subscribe
December 3, 2018
Press Release

BEND, Ore.--(BUSINESS WIRE)--PRESS RELEASE--EVIO Inc., a provider of cannabis testing and scientific research for the regulated cannabis industry in North America, has announced it now meets California’s Phase 3 cannabis compliance testing requirements. Starting Jan. 1, 2019, the Bureau of Cannabis Control requires additional testing for terpenoids, mycotoxins, heavy metals and water activity. The regulations set forth by the BCC requires licensed retailers to only sell cannabis goods that have met all state-mandated testing requirements.

EVIO Labs Berkeley is one of the first of California’s fully ISO 17025-accredited labs prepared to offer Phase 3 compliance testing. The lab has continued to realize an increased demand for its services and is preparing for the additional projected increase in volume by expanding the lab.

“We are getting inquiries about our services from dozens of high-profile distributors from across the state. Similarly, the number of potential clients with whom we are actively engaged in contracting discussions grows significantly every day,” stated Al Lustig, president of EVIO. “With the pending Phase 3 deadline, the urgency with which licensed distributors search for a compliant cannabis testing laboratory continues to grow. Being one of the few labs ready to offer Phase 3 testing, we are forecasting a significant increase in demand for our services. To minimize impact to our client turn-around times, EVIO Labs Berkeley is currently hiring additional staff and procuring additional equipment for increased capacity and redundancy.”

The opportunities remain vast. According to the Bureau of Cannabis Control, since July 1st, 2018, 22,096 batches of cannabis product were fully compliance tested by licensed cannabis laboratories in California. With a number of licensees still coming on line, we project testing volume will double in the next six months. EVIO recently announced their preliminary fourth quarter 2018 earnings where CEO William Waldrop stated a quarterly growth of 66 percent with revenues exceeding $1 million dollars.